Furthermore, we revealed that Rac1 inhibition can reverse melanoma growth and metastasis caused by high kindlin-2 expression, and combination therapy with a Rac1 inhibitor and vemurafenib can result in a better therapeutic outcome than monotherapy in melanoma patients with high kindlin-2 expression and BRAF mutations (Fig. 8). Here, RAC1 is linked to melanoma.